DXCM
DexCom, Inc.NASDAQHealthcareAs of 2026-04-06
Valuation
View DetailsP/E (TTM)
29.02
PEG
0.64
P/B
8.76
P/S
5.21
EV/EBITDA
18.51
DCF Value
$32.38
FCF Yield
4.4%
Div Yield
0.0%
Margins & Returns
Gross Margin
60.1%
Operating Margin
19.6%
Net Margin
17.9%
ROE
32.4%
ROA
13.4%
ROIC
16.6%
Financials
View All| Period | Revenue | Net Income | EPS |
|---|---|---|---|
| Q4 2025 | $1.26B | $267.3M | $0.67 |
| FY 2025 | $4.66B | $836.3M | $2.09 |
| Q3 2025 | $1.21B | $283.8M | $0.70 |
| Q2 2025 | $1.16B | $179.8M | $0.45 |
Analyst Ratings
View AllTrading Activity
Insider Trades
View AllCongress Trades
View AllCompany Info
Sector
Healthcare
Industry
—
Country
US
Exchange
NASDAQ
Beta
1.56
DexCom, Inc., a medical device company, focuses on the design, development, and commercialization of continuous glucose monitoring (CGM) systems in the United States and internationally. The company provides its systems for use by people with diabetes, as well as for use by healthcare providers. Its products include DexCom G6, an integrated CGM system for diabetes management; Dexcom Real-Time API, which enables invited third-party developers to integrate real-time CGM data into their digital health applications and devices; Dexcom ONE, that is designed to replace finger stick blood glucose testing for diabetes treatment decisions; and Dexcom Share, a remote monitoring system. The company's products candidature comprises Dexcom G7, a next generation G7 CGM system. DexCom, Inc. has a collaboration and license agreement with Verily Life Sciences LLC and Verily Ireland Limited to develop blood-based or interstitial glucose monitoring products. The company markets its products directly to endocrinologists, physicians, and diabetes educators. DexCom, Inc. was incorporated in 1999 and is headquartered in San Diego, California.